生物活性
TRV130 hydrochloride (Oliceridine,奥塞利定) 是一种新型的μ-阿片类受体(MOR)G蛋白偏向的配体。TRV130能引起强大的G蛋白信号传导,但由于β-restin 2的招募和受体的内化要少得多,它显示的不良反应更少。
使用AbMole产品发表的文献
产品使用成果展示
|
数据来源 |
Anesthesia & Analgesia (2018 Jul). Figure 5. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
方法 |
CPP assay |
细胞系/动物模型 |
mice |
浓度 |
1.25 or 10 mg/kg |
处理时间 |
7 d |
实验结果 |
Figure 5 shows that TLR4 mRNA expression was increased in the lumbar spinal cord tissue of fracture mice that received morphine at 3 weeks after injury(P < .05), while no such changes were observed in the fracture mice by the administration of oliceridine (P> .05). |
|
数据来源 |
Anesthesia & Analgesia (2018 Jul). Figure 4. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
方法 |
CPP assay |
细胞系/动物模型 |
mice |
浓度 |
5 μL/injection |
处理时间 |
7 d |
实验结果 |
The small amount of ethanol in the oliceridine vehicle (5 μL/injection) did not appear to affect nociceptive sensitivity as demonstrated in Figure 4. |
|
数据来源 |
Anesthesia & Analgesia (2018 Jul). Figure 3. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
方法 |
CPP assay |
细胞系/动物模型 |
mice |
浓度 |
1.25 or 10 mg/kg |
处理时间 |
3 d |
实验结果 |
However, a dose of oliceridine providing similar levels of analgesia, 1.25 mg/kg, did not cause statistically significant CPP (P > .05). |
|
数据来源 |
Anesthesia & Analgesia (2018 Jul). Figure 2. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
方法 |
CPP assay |
细胞系/动物模型 |
mice |
浓度 |
1.25 or 10 mg/kg |
处理时间 |
3 d |
实验结果 |
Figure 2 shows that both chronic oliceridine and morphine treatment reduced the mechanical paw withdraw thresholds in comparison with the baseline thresholds (P < .001). |
|
数据来源 |
Anesthesia & Analgesia (2018 Jul). Figure 1. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
方法 |
chronic administration |
细胞系/动物模型 |
mice |
浓度 |
5 mg/kg twice per day on days 1-3 and on day 4, 10 mg/kg |
处理时间 |
4 days |
实验结果 |
Figure 1A, B and the Table show that oliceridine dose–response curves were not significantly changed before and after chronic dosing (P > .05). |
|
数据来源 |
J Psychopharmacol (2017). Figure 1. TRV130 |
方法 |
injection |
细胞系/动物模型 |
mice |
浓度 |
100 nM |
处理时间 |
24h |
实验结果 |
In the repeated-vehicle treatment group, vehicle administration on Day 4 did not produce antinociception, and mice displayed high fecal output, whereas 10 mg/kg (+)-TRV130 produced maximal antinociception in all mice and nearly maximal suppression of fecal output. In the 3-day (+)-TRV130 treatment group |
化学性质
分子量 |
423.01 |
分子式 |
C22H31ClN2O2S |
CAS号 |
1401031-39-7
|
溶解性(25°C) |
DMSO ≥ 35 mg/mL |
储存条件 |
粉末型式 -20°C 3年;4°C 2年
溶于溶剂 -80°C 6个月;-20°C 1个月
|
运输方式 |
冰袋运输,根据产品的不同,可能会有相应调整。 |
储备液配制
*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
2.364 mL |
11.8201 mL |
23.6401 mL |
5 mM |
0.4728 mL |
2.364 mL |
4.728 mL |
10 mM |
0.2364 mL |
1.182 mL |
2.364 mL |
不同实验动物依据体表面积的等效剂量转换表(参考来源于公开文献)
|
小鼠 |
大鼠 |
兔 |
豚鼠 |
仓鼠 |
狗 |
重量 (kg) |
0.02 |
0.15 |
1.8 |
0.4 |
0.08 |
10 |
体表面积 (m2) |
0.007 |
0.025 |
0.15 |
0.05 |
0.02 |
0.5 |
Km 系数 |
3 |
6 |
12 |
8 |
5 |
20 |
动物 A (mg/kg) = 动物 B (mg/kg) × |
动物 B的Km系数
|
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
参考文献
[1] Soergel DG, et al. Pain. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.
[2] Violin JD, et al. Trends Pharmacol Sci. Biased ligands at G-protein-coupled receptors: promise and progress.
[3] Soergel DG, et al. J Clin Pharmacol. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. Soergel DG1, Subach RA, Sadler B, Connell J, Marion AS, Cowan CL, Violin JD, Lark MW.
[4] Chen XT, et al. J Med Chem. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.